Mark E Robson

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications
    Michael A Postow
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Sarcoma Res 2:16. 2012
  2. pmc Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
    Anna Marie Mulligan
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
    Breast Cancer Res 13:R110. 2011
  3. pmc Frequency of CHEK2*1100delC in New York breast cancer cases and controls
    Kenneth Offit
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BMC Med Genet 4:1. 2003
  4. ncbi request reprint BRCA-associated breast cancer: absence of a characteristic immunophenotype
    M Robson
    Department of Human Genetics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 58:1839-42. 1998
  5. ncbi request reprint Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia
    Mark E Robson
    Clinical Genetics and Gastrointestinal Oncology Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 10:1250-4. 2004
  6. ncbi request reprint Clinical practice. Management of an inherited predisposition to breast cancer
    Mark Robson
    Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    N Engl J Med 357:154-62. 2007
  7. ncbi request reprint Breast cancer surveillance in women with hereditary risk due to BRCA1 or BRCA2 mutations
    Mark Robson
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Breast Cancer 5:260-8; discussion 269-71. 2004
  8. ncbi request reprint Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series
    Mark Robson
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 103:44-51. 2005
  9. ncbi request reprint Treatment of hereditary breast cancer
    Mark E Robson
    Clinical Genetics and Breast Cancer Medicine Services, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 34:384-91. 2007
  10. ncbi request reprint Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy
    Mark Robson
    Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 89:281-7. 2003

Detail Information

Publications46

  1. pmc Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications
    Michael A Postow
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Sarcoma Res 2:16. 2012
    ....
  2. pmc Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
    Anna Marie Mulligan
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
    Breast Cancer Res 13:R110. 2011
    ..It is currently unknown how these alleles are associated with different breast cancer subtypes in BRCA1 and BRCA2 mutation carriers defined by estrogen (ER) or progesterone receptor (PR) status of the tumour...
  3. pmc Frequency of CHEK2*1100delC in New York breast cancer cases and controls
    Kenneth Offit
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BMC Med Genet 4:1. 2003
    ..While the frequency of 1100delC was 1.1-1.4% in healthy Finnish controls, the frequency of this allele in a North American control population and in North American breast cancer kindreds remains unclear...
  4. ncbi request reprint BRCA-associated breast cancer: absence of a characteristic immunophenotype
    M Robson
    Department of Human Genetics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 58:1839-42. 1998
    ..Additional studies of BABC are required to determine the nature and implications of additional genetic abnormalities occurring in these tumors...
  5. ncbi request reprint Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia
    Mark E Robson
    Clinical Genetics and Gastrointestinal Oncology Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 10:1250-4. 2004
    ..Preliminary correlations between the site of mutation and the clinical phenotype have been proposed, but the strength of these associations is not defined...
  6. ncbi request reprint Clinical practice. Management of an inherited predisposition to breast cancer
    Mark Robson
    Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    N Engl J Med 357:154-62. 2007
  7. ncbi request reprint Breast cancer surveillance in women with hereditary risk due to BRCA1 or BRCA2 mutations
    Mark Robson
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Breast Cancer 5:260-8; discussion 269-71. 2004
    ....
  8. ncbi request reprint Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series
    Mark Robson
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 103:44-51. 2005
    ..The current study evaluates the appropriateness of breast-conserving therapy (BCT) in women with BRCA mutations...
  9. ncbi request reprint Treatment of hereditary breast cancer
    Mark E Robson
    Clinical Genetics and Breast Cancer Medicine Services, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 34:384-91. 2007
    ..The well-documented increased risk of contralateral second primary breast cancer and possibly of late ipsilateral second primary breast cancers may influence patient decision-making with regard to breast-conserving treatment...
  10. ncbi request reprint Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy
    Mark Robson
    Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 89:281-7. 2003
    ..We studied women who had undergone RRSO to assess quality of life after the procedure...
  11. ncbi request reprint Clinical considerations in the management of individuals at risk for hereditary breast and ovarian cancer
    Mark E Robson
    Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Control 9:457-65. 2002
    ..The optimal clinical management of individuals with such a predisposition is not yet completely defined...
  12. ncbi request reprint BRCA-associated breast cancer in young women
    M Robson
    Department of Human Genetics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 16:1642-9. 1998
    ..To delineate the clinical characteristics and outcomes of breast cancer that arises in the setting of a germline BRCA mutation and to compare BRCA-associated breast cancers (BABC) with those that arise in women without mutations...
  13. ncbi request reprint Considerations in genetic counseling for inherited breast cancer predisposition
    Mark E Robson
    Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Radiat Oncol 12:362-70. 2002
    ..Genetic testing may play an important role in refining risk assessment, identifying individuals at risk before cancer has developed, and relieving anxiety in family members who have not inherited the predisposition...
  14. ncbi request reprint Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations
    M Robson
    Departments of Human Genetics and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Natl Cancer Inst 91:2112-7. 1999
    ..Consequently, we compared the outcomes after breast conservation therapy in Ashkenazi women with or without germline mutations in BRCA1 and/or BRCA2 (hereafter called BRCA)...
  15. ncbi request reprint Are BRCA1- and BRCA2-associated breast cancers different? Prognosis of BRCA1-associated breast cancer
    M Robson
    Departments of Human Genetics and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 18:113S-8S. 2000
    ..To review the available literature regarding the outcome of breast cancer arising in the setting of a germline BRCA1 mutation...
  16. ncbi request reprint Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis
    Tari A King
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg Oncol 14:2510-8. 2007
    ..However, several lines of evidence suggest that phenotypic effects may result from BRCA haploinsufficiency...
  17. ncbi request reprint Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families
    Noah D Kauff
    Department of Gynecology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Natl Cancer Inst 97:1382-4. 2005
    ..66 was expected (SIR = 1.52, 95% CI = 0.02 to 8.46; P = .48). These results suggest that women from BRCA mutation-negative, site-specific breast cancer families are not at increased risk for ovarian cancer...
  18. doi request reprint Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families
    Zsofia K Stadler
    Department of Medicine, Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 192, New York, NY 10021, USA
    Breast Cancer Res Treat 123:581-5. 2010
    ..Major gene rearrangements involving the BRCA1 and BRCA2 genes appear to contribute little to the burden of inherited predisposition to breast and ovarian cancer in the Ashkenazim...
  19. doi request reprint Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer
    Zsofia K Stadler
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 118:493-9. 2012
    ..Breast-pancreas cancer families with BRCA1 mutations have also been observed. The influence of a family history (FH) of PC on BRCA mutation prevalence in patients with breast cancer (BC) is unknown...
  20. ncbi request reprint Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations
    Douglas A Levine
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:4222-7. 2003
    ....
  21. pmc Germline BRCA mutations denote a clinicopathologic subset of prostate cancer
    David J Gallagher
    Clinical Genetics Service, Department of Medicine, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 16:2115-21. 2010
    ..Increased prostate cancer risk has been reported for BRCA mutation carriers, but BRCA-associated clinicopathologic features have not been clearly defined...
  22. pmc Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study
    Noah D Kauff
    Clinical Genetics and Gynecology Services, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 192, New York, NY 10021, USA
    J Clin Oncol 26:1331-7. 2008
    ....
  23. ncbi request reprint Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation
    Noah D Kauff
    Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    N Engl J Med 346:1609-15. 2002
    ..We prospectively compared the effect of risk-reducing salpingo-oophorectomy with that of surveillance for ovarian cancer on the incidence of subsequent breast cancer and BRCA-related gynecologic cancers in women with BRCA mutations...
  24. ncbi request reprint Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations
    Noah D Kauff
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 97:1601-8. 2003
    ....
  25. ncbi request reprint Increased progesterone receptor expression in benign epithelium of BRCA1-related breast cancers
    Tari A King
    Departments of Surgery, Pathology, Epidemiology and Biostatistics, and Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Res 64:5051-3. 2004
    ..We conclude that deregulation of progesterone receptor expression, as a result of BRCA1 haploinsufficiency, may represent an early event in BRCA1-linked breast tumorigenesis...
  26. pmc An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions
    Maeve A Lowery
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Oncologist 16:1397-402. 2011
    ....
  27. pmc Genome-wide association studies of cancer
    Zsofia K Stadler
    Clinical Genetics Service andthe Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, NY, NY 10021, USA
    J Clin Oncol 28:4255-67. 2010
    ..To date, however, the clinical utility of GWAS-derived risk markers remains limited...
  28. pmc BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma
    Cristina R Ferrone
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 27:433-8. 2009
    ....
  29. ncbi request reprint Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up
    Noah D Kauff
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:314-20. 2005
    ..Limited information is available regarding the impact of this approach on either quality of life (QOL) or need for invasive follow-up in this group of women...
  30. ncbi request reprint Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life
    Martee L Hensley
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1278 York Avenue, New York, NY 10021 6094, USA
    Gynecol Oncol 89:440-6. 2003
    ..We sought to determine whether anxiety, depression, perception of ovarian cancer risk, and false-positive test frequency differed between high-risk premenopausal and postmenopausal women initiating ovarian cancer screening...
  31. ncbi request reprint Evaluation of germline PTEN mutations in endometrial cancer patients
    Destin Black
    Gynecology and Breast Research Laboratory, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 96:21-4. 2005
    ..The aim of this study was to test whether a substantial proportion of endometrial cancers are associated with germline mutations of the PTEN gene, not necessarily in association with clinically overt Cowden syndrome...
  32. ncbi request reprint BRCA mutations and risk of prostate cancer in Ashkenazi Jews
    Tomas Kirchhoff
    Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 10:2918-21. 2004
    ..Several series looking at the frequency of BRCA mutations in unselected patients with prostate cancer have not confirmed this finding. To clarify this issue, we conducted a large case-control study...
  33. doi request reprint Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysis
    Carmen A Perez
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Breast Cancer Res Treat 139:497-506. 2013
    ..Black women with TNBC had equivalent local control, but higher risk of regional nodal failure, compared with non-black counterparts. The routine use of comprehensive nodal irradiation may be beneficial for black women with TNBC...
  34. doi request reprint Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy
    Alice Y Ho
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 118:4944-52. 2012
    ..The authors evaluated the clinical characteristics, natural history, and outcomes of patients who had ≤1 cm, lymph node-negative, triple-negative breast cancer (TNBC)...
  35. doi request reprint Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer
    David J Gallagher
    Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 109:713-9. 2012
    ....
  36. doi request reprint Germline PALB2 mutation analysis in breast-pancreas cancer families
    Zsofia K Stadler
    Clinical Genetics and Gastroenterology Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    J Med Genet 48:523-5. 2011
    ..Germline mutations in the PALB2 gene have been implicated in both breast cancer and pancreatic cancer susceptibility. The extent to which PALB2 mutations account for cancer susceptibility in breast-pancreas cancer families is unknown...
  37. pmc Genetic analysis of the early natural history of epithelial ovarian carcinoma
    Bhavana Pothuri
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    PLoS ONE 5:e10358. 2010
    ....
  38. pmc Screening for germline EGFR T790M mutations through lung cancer genotyping
    Geoffrey R Oxnard
    Thoracic Oncology Service and Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Thorac Oncol 7:1049-52. 2012
    ..We hypothesized that patients with lung cancers found to harbor the EGFR T790M resistance mutation before treatment, an uncommon occurrence, would be likely to carry underlying germline T790M mutations...
  39. ncbi request reprint Update on hereditary breast cancer
    Karen Lisa Smith
    Memorial Sloan Kettering Cancer Center, Clinical Genetics and Breast Cancer Medicine Services, Department of Medicine, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 8:14-21. 2006
    ..Preclinical data suggest that BRCA mutation-associated breast cancers may benefit from specific targeted therapeutic approaches...
  40. pmc A note on competing risks in survival data analysis
    J M Satagopan
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Br J Cancer 91:1229-35. 2004
    ..We compare the resulting estimates with those obtained using the Kaplan-Meier approach to demonstrate the importance of appropriately estimating the cumulative incidence of an event of interest in the presence of competing risk events...
  41. ncbi request reprint Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer
    Chau T Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 10:5754-61. 2004
    ..The primary objective was to determine the feasibility of the regimen; the secondary objective was to estimate the disease-free and overall survival...
  42. ncbi request reprint Tamoxifen for primary breast cancer prevention in BRCA heterozygotes
    M Robson
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Eur J Cancer 38:S18-9. 2002
  43. ncbi request reprint Protecting the privacy of third-party information: recommendations for social and behavioral health researchers
    David W Lounsbury
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Soc Sci Med 64:213-22. 2007
    ..We assert that these recommendations protect the rights of, and minimize the risks to, third parties without impeding social and behavioral health research...
  44. ncbi request reprint Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer
    T A Traina
    Memorial Sloan Kettering Cancer Center, Breast Cancer Medicine Service, New York, NY 10021, USA
    Breast Cancer Res Treat 111:377-88. 2008
    ..Preclinical evidence suggests a rationale for coadministration of these agents to achieve complete estrogen blockade...
  45. pmc A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment
    Mark E Robson
    Research Institute of McGill University Health Centre, Cancer Prevention Centre, McGill University, Montreal, Quebec, Canada
    Breast Cancer Res 6:R8-R17. 2004
    ..The prognostic significance of germline mutations in BRCA1 and BRCA2 in women with breast cancer remains unclear. A combined analysis was performed to address this uncertainty...
  46. ncbi request reprint Breast MRI for women with hereditary cancer risk
    Mark E Robson
    JAMA 292:1368-70. 2004